Geopolitical and macroeconomic uncertainties
Management cited external environment risks including shipping disruptions and US inflationary pressures, leading to conservative guidance.
SENORESPHARMACEUTICALS / Q4-FY26 / risks
Keep the risk register visible.
Senores Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Working capital days increase
Working capital days rose to 187 days in FY26 from 114 days in FY25, partly due to inventory buildup for new launches. Management expects normalization.
Unbilled revenue buildup
Other financial assets (unbilled revenue) increased to 172 crores from 116 crores, reflecting profit share recognition before cash realization. Management expects plateauing.
Execution risk on ANDA commercialization
30 approved ANDAs are yet to be launched; delays in commercialization could impact revenue visibility.